SpringWorks Therapeutics Inc. (SWTX) Reports Interim Data from Phase 2b ReNeu Trial of Mirdametinib for Patients with NF1-PN and Provides Trial Update
Go back to SpringWorks Therapeutics Inc. (SWTX) Reports Interim Data from Phase 2b ReNeu Trial of Mirdametinib for Patients with NF1-PN and Provides Trial UpdateSouthwall Technologies, Inc. (NASDAQ: SWTX) | Delayed: 44.20 +0.82 (1.89%) | |||||
---|---|---|---|---|---|---|
Previous Close | $43.38 | 52 Week High | $14.00 | |||
Open | $42.59 | 52 Week Low | $1.92 | |||
Day High | $45.20 | P/E | 56.67 | |||
Day Low | $41.75 | EPS | $0.78 | |||
Volume | 999,789 |